Long-term oral enoximone therapy in chronic cardiac failure

Carol S. Maskin, Karl Weber, Joseph S. Janicki

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Sixty-nine patients with chronic heart failure of moderate to advanced severity were treated with oral enoximone (mean dose 1.8 ± 0.5 mg/kg every 6 to 8 hours) for an average of 35 weeks (range 1 to 129). Before long-term therapy in 56 patients, oral enoximone was shown to augment cardiac output by more than 30%. In 13 outpatients enoximone was initiated without hemodynamic monitoring. Within 12 weeks of therapy the majority of surviving patients were improved by at least 1 New York Heart Association functional class. In a subset of 30 patients who were able to perform reproducible treadmill exercise before entry, average maximal O2 uptake increased from 14.9 ml/kg/min at baseline to 17.6 ml/kg/min (p < 0.05) at 2 to 4 weeks and remained increased at 17.4 ml/kg/min (p < 0.05) at 12 weeks. Adverse gastrointestinal effects occurred in 11 patients and were generally mild. The 12 month survival rate was 44%; etiology of death was cardiogenic shock in 17 patients and 10 patients died suddenly while at home. Thus, improvements in symptoms and maximal v̇O2 were observed in many patients with moderate to severe heart failure during long-term therapy with enoximone. Controlled trials will be needed to establish the safety and efficacy of this promising new drug.

Original languageEnglish (US)
Pages (from-to)63-67
Number of pages5
JournalThe American Journal of Cardiology
Volume60
Issue number5
DOIs
StatePublished - Aug 14 1987
Externally publishedYes

Fingerprint

Enoximone
Heart Failure
Therapeutics
Cardiogenic Shock
Cardiac Output
Outpatients
Survival Rate
Hemodynamics
Exercise
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Long-term oral enoximone therapy in chronic cardiac failure. / Maskin, Carol S.; Weber, Karl; Janicki, Joseph S.

In: The American Journal of Cardiology, Vol. 60, No. 5, 14.08.1987, p. 63-67.

Research output: Contribution to journalArticle

Maskin, Carol S. ; Weber, Karl ; Janicki, Joseph S. / Long-term oral enoximone therapy in chronic cardiac failure. In: The American Journal of Cardiology. 1987 ; Vol. 60, No. 5. pp. 63-67.
@article{db06b5ecdea94607bb33e13a36f0c076,
title = "Long-term oral enoximone therapy in chronic cardiac failure",
abstract = "Sixty-nine patients with chronic heart failure of moderate to advanced severity were treated with oral enoximone (mean dose 1.8 ± 0.5 mg/kg every 6 to 8 hours) for an average of 35 weeks (range 1 to 129). Before long-term therapy in 56 patients, oral enoximone was shown to augment cardiac output by more than 30{\%}. In 13 outpatients enoximone was initiated without hemodynamic monitoring. Within 12 weeks of therapy the majority of surviving patients were improved by at least 1 New York Heart Association functional class. In a subset of 30 patients who were able to perform reproducible treadmill exercise before entry, average maximal O2 uptake increased from 14.9 ml/kg/min at baseline to 17.6 ml/kg/min (p < 0.05) at 2 to 4 weeks and remained increased at 17.4 ml/kg/min (p < 0.05) at 12 weeks. Adverse gastrointestinal effects occurred in 11 patients and were generally mild. The 12 month survival rate was 44{\%}; etiology of death was cardiogenic shock in 17 patients and 10 patients died suddenly while at home. Thus, improvements in symptoms and maximal v̇O2 were observed in many patients with moderate to severe heart failure during long-term therapy with enoximone. Controlled trials will be needed to establish the safety and efficacy of this promising new drug.",
author = "Maskin, {Carol S.} and Karl Weber and Janicki, {Joseph S.}",
year = "1987",
month = "8",
day = "14",
doi = "10.1016/0002-9149(87)90528-5",
language = "English (US)",
volume = "60",
pages = "63--67",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Long-term oral enoximone therapy in chronic cardiac failure

AU - Maskin, Carol S.

AU - Weber, Karl

AU - Janicki, Joseph S.

PY - 1987/8/14

Y1 - 1987/8/14

N2 - Sixty-nine patients with chronic heart failure of moderate to advanced severity were treated with oral enoximone (mean dose 1.8 ± 0.5 mg/kg every 6 to 8 hours) for an average of 35 weeks (range 1 to 129). Before long-term therapy in 56 patients, oral enoximone was shown to augment cardiac output by more than 30%. In 13 outpatients enoximone was initiated without hemodynamic monitoring. Within 12 weeks of therapy the majority of surviving patients were improved by at least 1 New York Heart Association functional class. In a subset of 30 patients who were able to perform reproducible treadmill exercise before entry, average maximal O2 uptake increased from 14.9 ml/kg/min at baseline to 17.6 ml/kg/min (p < 0.05) at 2 to 4 weeks and remained increased at 17.4 ml/kg/min (p < 0.05) at 12 weeks. Adverse gastrointestinal effects occurred in 11 patients and were generally mild. The 12 month survival rate was 44%; etiology of death was cardiogenic shock in 17 patients and 10 patients died suddenly while at home. Thus, improvements in symptoms and maximal v̇O2 were observed in many patients with moderate to severe heart failure during long-term therapy with enoximone. Controlled trials will be needed to establish the safety and efficacy of this promising new drug.

AB - Sixty-nine patients with chronic heart failure of moderate to advanced severity were treated with oral enoximone (mean dose 1.8 ± 0.5 mg/kg every 6 to 8 hours) for an average of 35 weeks (range 1 to 129). Before long-term therapy in 56 patients, oral enoximone was shown to augment cardiac output by more than 30%. In 13 outpatients enoximone was initiated without hemodynamic monitoring. Within 12 weeks of therapy the majority of surviving patients were improved by at least 1 New York Heart Association functional class. In a subset of 30 patients who were able to perform reproducible treadmill exercise before entry, average maximal O2 uptake increased from 14.9 ml/kg/min at baseline to 17.6 ml/kg/min (p < 0.05) at 2 to 4 weeks and remained increased at 17.4 ml/kg/min (p < 0.05) at 12 weeks. Adverse gastrointestinal effects occurred in 11 patients and were generally mild. The 12 month survival rate was 44%; etiology of death was cardiogenic shock in 17 patients and 10 patients died suddenly while at home. Thus, improvements in symptoms and maximal v̇O2 were observed in many patients with moderate to severe heart failure during long-term therapy with enoximone. Controlled trials will be needed to establish the safety and efficacy of this promising new drug.

UR - http://www.scopus.com/inward/record.url?scp=0023195006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023195006&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(87)90528-5

DO - 10.1016/0002-9149(87)90528-5

M3 - Article

VL - 60

SP - 63

EP - 67

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 5

ER -